Menu
Directory
Directory

COVID Frontline

Directory

Podcast & CME Activities

Podcast

Online Programs

TeleECHO Sessions

CLICK ON STATES TO SEE LIVE ACTIVITIES

Podcast

[ai1ec cat_name=”Podcast” ]

Online Programs

[ai1ec cat_name=”ECHOS” events_limit=”12″]

ONLINE ACTIVITIES

[ai1ec cat_name=”Online Programs” events_limit=”6″]

BOOTH TOUR

[ai1ec cat_name=”Booth” ]
[ai1ec cat_name=”MEDS Meetings” ]

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

[ai1ec cat_name=”NACE Meetings” ]
[ai1ec cat_name=”PriMed Booths” ]

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Scroll to Top
Directory
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill